Gene therapy cut cornstarch dependence by 41% in glycogen storage disease type Ia

Design

Pivotal phase 3, double-blind, randomised, placebo-controlled trial with a blinded crossover period (DTX401-CL301)

Population

46 patients aged 8 years and over with glycogen storage disease type Ia; 21 received DTX401 and 25 placebo

Primary outcome

Percent change from baseline to week 48 in daily cornstarch intake

Effect

Least-squares mean reduction 41% (SE 4.6) vs 10% (4.1) on placebo, p<0.0001; larger and faster reductions in the crossover group by week 96

Glycogen storage disease type Ia is managed by never letting blood glucose fall, which in practice means uncooked cornstarch every few hours, day and night, for life. DTX401 is an AAV8 vector carrying the human G6PC gene, and DTX401-CL301 is its pivotal trial: phase 3, double-blind, randomised and placebo-controlled in patients aged 8 and over, with a 48-week primary period followed by a blinded crossover.

21 participants received DTX401 and 25 placebo. At week 48 the least-squares mean reduction in daily cornstarch intake was 41% (SE 4.6) against 10% (4.1) on placebo, p<0.0001. The trial anchored that against what patients themselves wanted: among 33 interviewed at baseline, the mean desired reduction was 45% and the median 41% - so the effect achieved was close to the effect asked for, which is a more meaningful benchmark than statistical significance. At week 96 the crossover group had larger and faster reductions than the original treatment group had shown in the primary period. Transaminase rises occurred as expected for hepatic AAV therapy and were managed with prophylactic corticosteroids.

This is a small trial in a rare disease, and the endpoint is cornstarch intake rather than hypoglycaemic events, growth or long-term hepatic outcomes. Durability of AAV gene expression over years is the open question for this whole class, and 96 weeks does not answer it.

What it means practically, for now, is that a family living on scheduled overnight feeds may have a realistic prospect of fewer of them. Nothing about access has changed - this is an investigational product and its Indian regulatory position is not addressed here - so the appropriate action is referral to a metabolic centre and trial registries, not a promise.

• The endpoint is cornstarch intake, not hypoglycaemia or growth - do not present it as cure
• Expect transaminase rises with hepatic AAV therapy; prophylactic corticosteroids were used here
• Durability beyond two years is unknown for this class - counsel families accordingly
• Refer suspected glycogen storage disease to a metabolic centre for genotyping, which trial access requires
• The desired-reduction interviews are worth copying: ask patients what change would matter before you measure one

The statistics, in plain English

A 41% versus 10% reduction with standard errors of about 4.5 is a clear separation, and p<0.0001 in 46 patients means the difference is very unlikely to be chance - it says nothing about how long it lasts. The comparison against patients' own stated desired reduction is unusual and useful: it converts a percentage into a question about whether the change is worth having. What the trial cannot tell you is whether less cornstarch translates into fewer hypoglycaemic episodes or better growth, because those were not the primary endpoint.

Read the rest in the app

You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.

Get Daily Doctor — free

Scan to keep reading on your phone. No account needed to start.